JP2023529926A5 - - Google Patents
Info
- Publication number
- JP2023529926A5 JP2023529926A5 JP2022576040A JP2022576040A JP2023529926A5 JP 2023529926 A5 JP2023529926 A5 JP 2023529926A5 JP 2022576040 A JP2022576040 A JP 2022576040A JP 2022576040 A JP2022576040 A JP 2022576040A JP 2023529926 A5 JP2023529926 A5 JP 2023529926A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- optionally substituted
- groups
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2008749.0A GB202008749D0 (en) | 2020-06-09 | 2020-06-09 | Novel compounds |
| GB2008749.0 | 2020-06-09 | ||
| PCT/GB2021/051428 WO2021250399A1 (en) | 2020-06-09 | 2021-06-09 | 4-ethynylpyridine derivatives useful as gcn2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023529926A JP2023529926A (ja) | 2023-07-12 |
| JP2023529926A5 true JP2023529926A5 (cg-RX-API-DMAC7.html) | 2025-12-04 |
Family
ID=71616023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022576040A Pending JP2023529926A (ja) | 2020-06-09 | 2021-06-09 | Gcn2阻害剤として有用な4-エチニルピリジン誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20230271939A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4161915A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023529926A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230058042A (cg-RX-API-DMAC7.html) |
| CN (2) | CN116113629B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021289535A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022025147A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3181909A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB202008749D0 (cg-RX-API-DMAC7.html) |
| IL (1) | IL298860B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022015516A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021250399A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202008749D0 (en) | 2020-06-09 | 2020-07-22 | Ip2Ipo Innovations Ltd | Novel compounds |
| GB202104635D0 (en) | 2021-03-31 | 2021-05-12 | Imperial College Innovations Ltd | Methods and compositions for identifying and treating GCN2-dependent cancers |
| GB202118096D0 (en) * | 2021-12-14 | 2022-01-26 | Ip2Ipo Innovations Ltd | Novel compounds |
| GB202403113D0 (en) | 2024-03-04 | 2024-04-17 | Apollo Ap30 Ltd | Novel compounds |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7037927B2 (en) | 2003-10-16 | 2006-05-02 | Abbott Laboratories | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| WO2006082371A1 (en) | 2005-02-01 | 2006-08-10 | Astrazeneca Ab | Pyrimidine compounds having tie2 (tek) inhibitory activity |
| GB0502418D0 (en) | 2005-02-05 | 2005-03-16 | Astrazeneca Ab | Compounds |
| EP3045457B1 (en) | 2009-06-15 | 2018-05-09 | Nerviano Medical Sciences S.r.l. | Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors |
| US9409914B2 (en) | 2012-01-28 | 2016-08-09 | Merck Patent Gmbh | Triazolo[4,5-d]pyrimidine derivatives |
| EP2822948B1 (en) | 2012-03-07 | 2016-04-06 | Merck Patent GmbH | Triazolopyrazine derivatives |
| WO2014031928A2 (en) | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
| EP2917214B1 (en) | 2012-11-07 | 2019-08-28 | Nerviano Medical Sciences S.r.l. | Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors |
| CA2903903C (en) | 2013-03-05 | 2021-05-04 | Merck Patent Gmbh | Triazolo[4,5-d]pyrimidine derivatives for the treatment of diseases such as cancer |
| EP2964648B1 (en) | 2013-03-05 | 2016-11-16 | Merck Patent GmbH | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
| CN105732614B (zh) | 2014-12-09 | 2018-06-12 | 中国科学院广州生物医药与健康研究院 | 磺酰胺基芳基炔类化合物及其用途 |
| CN104829613B (zh) | 2015-04-13 | 2020-06-09 | 赤峰蒙广生物科技有限公司 | 二芳基取代的吡唑并环类衍生物、其制备方法及其在医药领域的应用 |
| PL3498693T3 (pl) * | 2016-08-10 | 2025-03-24 | Takeda Pharmaceutical Company Limited | Związek heterocykliczny |
| WO2018068739A1 (zh) | 2016-10-13 | 2018-04-19 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的炔基杂环类化合物 |
| CA3089762A1 (en) | 2018-01-29 | 2019-08-01 | Merck Patent Gmbh | Gcn2 inhibitors and uses thereof |
| AU2019212969B2 (en) * | 2018-01-29 | 2025-01-23 | Merck Patent Gmbh | GCN2 inhibitors and uses thereof |
| EP3802544A1 (en) | 2018-06-05 | 2021-04-14 | RAPT Therapeutics, Inc. | Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses |
| WO2020210828A1 (en) * | 2019-04-12 | 2020-10-15 | Hibercell, Inc. | (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions |
| US20230128972A1 (en) | 2020-01-31 | 2023-04-27 | Atomwise Inc. | Anat Inhibitors and Methods of Use Thereof |
| EP4107146A1 (en) | 2020-02-17 | 2022-12-28 | Alesta Therapeutics BV | Gcn2 modulator compounds |
| WO2021222147A1 (en) | 2020-04-27 | 2021-11-04 | Hibercell, Inc. | Heterocyclic gcn2 modulators |
| GB202008749D0 (en) | 2020-06-09 | 2020-07-22 | Ip2Ipo Innovations Ltd | Novel compounds |
| PE20231311A1 (es) | 2020-11-18 | 2023-08-24 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos |
| KR20240021143A (ko) | 2021-01-22 | 2024-02-16 | 히버셀, 인크. | Gcn2 조정 화합물 및 그의 용도 |
| US20240150345A1 (en) | 2021-01-22 | 2024-05-09 | Hibercell, Inc. | Gcn2 modulating compounds and uses thereof |
-
2020
- 2020-06-09 GB GBGB2008749.0A patent/GB202008749D0/en not_active Ceased
-
2021
- 2021-06-09 US US18/001,317 patent/US20230271939A1/en active Pending
- 2021-06-09 MX MX2022015516A patent/MX2022015516A/es unknown
- 2021-06-09 JP JP2022576040A patent/JP2023529926A/ja active Pending
- 2021-06-09 CN CN202180058556.4A patent/CN116113629B/zh active Active
- 2021-06-09 CA CA3181909A patent/CA3181909A1/en active Pending
- 2021-06-09 EP EP21735355.6A patent/EP4161915A1/en active Pending
- 2021-06-09 BR BR112022025147A patent/BR112022025147A2/pt unknown
- 2021-06-09 WO PCT/GB2021/051428 patent/WO2021250399A1/en not_active Ceased
- 2021-06-09 AU AU2021289535A patent/AU2021289535A1/en active Pending
- 2021-06-09 CN CN202411827368.5A patent/CN119661503A/zh active Pending
- 2021-06-09 KR KR1020237000394A patent/KR20230058042A/ko active Pending
-
2022
- 2022-12-06 IL IL298860A patent/IL298860B2/en unknown
-
2023
- 2023-03-28 US US18/191,772 patent/US11945799B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2719699T3 (en) | Triazolopyraziner particular, compositions thereof and methods of use thereof | |
| ES2747249T3 (es) | Derivados de 1-(5-(terc-butil)isoxazol-3-il)-3-(4-((fenil)etinil)fenil)urea y compuestos relacionados como inhibidores de FLT3 para el tratamiento de cáncer | |
| ES2793239T3 (es) | Inhibidores del bromodominio | |
| JP2022527796A5 (cg-RX-API-DMAC7.html) | ||
| ES2392489T3 (es) | Dicarbazoles y procedimientos de uso | |
| CN104513252B (zh) | 取代脲衍生物及其在药物中的应用 | |
| AU2019392232A1 (en) | RET inhibitors, pharmaceutical compositions and uses thereof | |
| JP7702057B2 (ja) | がんの治療のためのホスホイノシチド3-キナーゼ(pi3k)のアロステリッククロメノン阻害剤 | |
| RU2014130125A (ru) | Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| AU2009259867A1 (en) | Triazolopyridine JAK inhibitor compounds and methods | |
| CN102399233A (zh) | PI3K和mTOR双重抑制剂类化合物 | |
| CN111320624B (zh) | 三唑并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途 | |
| TW202229282A (zh) | 治療癌症之方法 | |
| KR20250004897A (ko) | 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제 | |
| AU2021204704B2 (en) | Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer | |
| RU2008130458A (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-c]ПИРИДИН-4-ОН 2-ИНДОЛИНОНА В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗЫ | |
| CN116283916A (zh) | 具有Axl与c-Met激酶抑制活性的化合物及其制备和应用 | |
| CN104513258B (zh) | 取代脲衍生物及其在药物中的应用 | |
| TW202131917A (zh) | 併用醫藥 | |
| WO2019104067A1 (en) | Co-therapies including a metastasis inhibitor | |
| CN117800964A (zh) | PI3K/m-TOR抑制剂及其应用 | |
| CN105461709B (zh) | 取代脲衍生物及其在药物中的应用 | |
| CN118894860A (zh) | 取代的杂环化合物 | |
| WO2025165835A1 (en) | Anilino tricyclic compounds, and compositions and methods thereof | |
| TWI690533B (zh) | Cdk類小分子抑制劑的化合物及其用途 |